1. Anti-infection
  2. Bacterial


Cat. No.: HY-B0356 Purity: 99.55%
Data Sheet SDS Handling Instructions

Ciprofloxacin is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.

For research use only. We do not sell to patients.
Ciprofloxacin Chemical Structure

Ciprofloxacin Chemical Structure

CAS No. : 85721-33-1

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
1 g $60 In-stock
5 g $90 In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References


Ciprofloxacin is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.

In Vivo

Ciprofloxacin (1 mg/L) induces GST activity, in contrast with inhibited GST and CAT of larvae exposed to enrofloxacin. Ciprofloxacin (≥10 μg/L) and enrofloxacin are ecotoxic for development, growth, detoxifying, and oxidative stress enzymes in anuran amphibian larvae[1]. Ciprofloxacin (CIP) shows potent activity against Y. pestis with MIC90 of 0.03 μg/mL[2]. In a murine model of pneumonic plague, ciprofloxacin (30 mg/kg, i.p.) results in a drug exposure which is similar to the drug exposure observed in humans following a 500 mg dose of oral ciprofloxacin. Intraperitoneal ciprofloxacin reduces the lung bacterial load compared to controls treated with intraperitoneal PBS[3].

Clinical Trial
View MoreCollapse
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 3.0180 mL 15.0902 mL 30.1805 mL
5 mM 0.6036 mL 3.0180 mL 6.0361 mL
10 mM 0.3018 mL 1.5090 mL 3.0180 mL
Please refer to the solubility information to select the appropriate solvent.
Animal Administration

Female BALB/cAnNCrl (BALB/c) mice, 8-10 weeks old and 20 g (±4 g) are used in this assay. A single dose of ciprofloxacin (30 mg/kg) is administered to mice (n=30) via the intraperitoneal (i.p.) route. The mice (n=3/time point/group) are culled at 1, 10, 20, or 30 min and 1, 1.5, 2, 4, 8, 12 h following ciprofloxacin administration and 1, 15, or 30 min and 1, 2, 4, 6, 10, 18, or 24 h following DRCFI or CFI administration. Blood sampling points are chosen based upon the short half-life of ciprofloxacin and longer half-life of CFI. Blood and lungs (whole organ) are collected post mortem for analysis. The lung doses following CFI or DRCFI administration are calculated using the concentration of ciprofloxacin in the lung samples at 1 min post-administration. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight






Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: < 0.1 mg/mL; Acetic acid: ≥ 165 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number


Organization name *

Country *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.: